David Albala, MD

David Albala, MD, shares closing advice on using PSMA-PET scans in prostate cancer management and making informed patient selection decisions based on guidelines and practical insights.

The significance of patient convenience, evolving imaging techniques, and recent breakthroughs in prostate cancer care, with a focus on the role of PSA-PET scanning in directing patient treatment.

David Albala, MD, discusses how starting October 1st, CMS will reimburse imaging centers directly, simplifying the process and removing reimbursement concerns for physicians ordering radiotracer tests.

Overview of hurdles and advancements in utilizing advanced imaging techniques for prostate cancer diagnosis, including agent availability, scheduling, facility preferences, and reimbursement.

Insight into advancements in prostate cancer imaging using PSMA agents like gallium and F-18, their unique characteristics, and the considerations in choosing the right radiotracer for accurate detection.

Explore the transformative journey of prostate cancer imaging techniques, from conventional methods to cutting-edge PET scans like F-18 PSMA, and how FDA approvals have shaped their adoption.

Join David Albala, MD, as he explores the use of advanced imaging techniques in prostate cancer diagnosis and management, highlighting PSMA-PET scans and their pivotal role in modern prostate cancer care.

Panelists review the recent FDA approval of the PSMA-targeted therapy Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer and discuss additional settings in which it, and other PSMA-targeted treatments, might be used in the future.

Drs Albala, Andriole, Ross, and Ulaner sum up recent advances and remaining unmet needs in the field of prostate cancer imaging and share hopes for the future.

Thought leaders discuss the possibility of using artificial intelligence to help interpret PSMA-PET results.

Panelists discuss how they typically document prostate cancer patient eligibility when ordering PSMA-PET imaging, and share strategies to optimize insurance coverage and reimbursement.

Gary Ulaner, MD, PhD, FACNM provides practical advice for radiologists who are generating PSMA-PET imaging reports, as well as for the urologists who are interpreting PSMA-PET results.

Shared insight from the panel on how they typically select radiotracers when ordering PSMA-PET scans in their clinical practice.

Citing recent guidelines recommendations, urologists share how they approach sequencing of conventional and PSMA-PET imaging for patients with prostate cancer, and discuss how use of each modality might affect subsequent patient management and treatment decisions.

Urologist Ashley Ross, MD, PhD leads a discussion of the benefits and limitations of PSMA-PET in patients with prostate cancer, as compared to older imaging modalities.

Radiologist Gary Ulaner, MD, PhD, FACNM provides a comprehensive discussion on the FDA-approved PSMA radiotracer options that are available for use as part of PSMA-PET imaging.

Panelists consider how they have incorporated some newer imaging modalities, including PSMA-PET, into their clinical practice, and discuss the terminology that urologists and radiologists have recently used to describe these modalities.

A focused discussion on prostate-specific membrane antigen (PSMA) as a target for imaging and treatment for patients with prostate cancer.

Expert panelists review risk stratification strategies for patients with prostate cancer and summarize the evolving use of conventional versus newer imaging modalities for diagnosis, treatment selection, and monitoring of these patients.

This article features insights from David Albala, MD, and Judd W. Moul, MD, on using liquid biomarker-based testing for the early detection of prostate cancer.

Expert urologists remark on unmet needs in prostate cancer by emphasizing the importance of reaching under-served communities, addressing patient discomfort, increasing education about liquid biopsy testing, and standardizing prostate size assessment.

Key opinion leaders in urology review factors to consider when selecting screening and risk-assessment tests for the diagnosis of prostate cancer including insurance coverage, commercial availability, and patient preference.

David Albala, MD and Judd W. Moul, MD consider the impact that COVID-19 has had on the clinical experience of patients with prostate cancer and share personal insights regarding telehealth and patient compliance.

Two experts in the management of prostate cancer provide key insight into the value of blood and urine liquid biopsy tests when deciding whether to perform a prostate tissue biopsy.

Thought leaders in the management of prostate cancer build a discussion on the challenges associated with the use of MRI to diagnose prostate cancer including insurance coverage and patient discomfort.

Experts urologists, David Albala, MD and Judd W. Moul, MD, compare the utility of a variety of blood and urine tests for screening and diagnosing prostate cancer.

Key opinion leaders in urology provide an overview of the prevalence of prostate cancer and discuss the importance of screening and risk assessment tools like the Prostate-Specific Antigen (PSA) test.

Christian Lawlor, BSc, Karl Miller, BSc, and David Albala, MD, explore the possible correlation.